Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ: NTRA )

173.39 +2.66 (+1.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,572,293
Open 171.52
Bid (Size) 174.50 (3)
Ask (Size) 179.00 (3)
Prev. Close 170.73
Today's Range 168.15 - 175.83
52wk Range 68.03 - 183.00
Shares Outstanding 132,020,816
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The S&P 500 Fights Through Challenging Headlines To Close At New Weekly All-Time Highs
In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire

Performance

YTD
+7.96%
+7.96%
1 Month
+2.90%
+2.90%
3 Month
+13.02%
+13.02%
6 Month
+40.08%
+40.08%
1 Year
+147.66%
+147.66%

More News

Read More
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
From Natera, Inc.
Via Business Wire
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA).
Via Chartmill
Looking Into Natera's Recent Short Interest
Via Benzinga
Small- To Mid-Cap Biotech Trades Poised For Gains
Via Talk Markets
Topics ETFs Stocks / Equities
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
Via Investor's Business Daily
The Analyst Verdict: Natera In The Eyes Of 14 Experts
Via Benzinga
Why NASDAQ:NTRA qualifies as a high growth stock.
Via Chartmill
Exploring NASDAQ:NTRA's high growth characteristics.
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
The End Of The 60/40 Portfolio
Via Benzinga
Topics Bonds
Exposures Debt Markets
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
From Natera, Inc.
Via Business Wire
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
From Natera, Inc.
Via Business Wire
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Via The Motley Fool
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Via The Motley Fool
Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%
Via Benzinga
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.